Author: Oparaji Chiedozie Kenneth
Department: Human Physiology
Affiliation: Nnamdi Azikiwe University Awka
The metabolic effects of serum prolactin perturbations are often overlooked. Recent data indicates a role for the prolactin hormone as a biomarker of cardiovascular risks. To study the effects of Bromocriptine and Metoclopramide on Lipid Profile, 40 male albino rats weighing between 150-180 grams were used. They were distributed into four groups of 10 rats each. Group I served as the negative control and were fed normal pelletized growers feed. Group II
served as the positive control and were fed a diet comprising normal rat feed mixed with 2.4% bleached palm oil extract. Group III received the same fat diet and a daily oral dose of 5mg/kg of the hypoprolactinaemic drug, Bromocriptine (Bromergon, Slovenia). Group IV also received the fat feed and were treated with a daily dose of 20mg/kg of Metoclopramide (Mederax, China), administered intraperitoneally to induce hyperprolactinemia.The animals were acclimatized for 14 days while treatment lasted for another 14 days. After treatment, their blood samples were
collected into sterile sample containers and the serum Prolactin (PRL) concentration was determined using ELISA Well Washer Stat Fax 2600 (Aware Technology Inc., USA) and ELISA Reader Stat Fax 2100 (Aware Technology Inc, USA). The Lipid Profile parameters – Total Cholesterol (TC), Triglycerides (TG), High Density Lipoproteins (HDL), and Low Density Lipoproteins – were determined usingTRSP-722 Spectrophotometer (TRIUP International corporation, China). There was a statistically significant difference (P0.05), the bromocriptine-treated rats showed lower mean TC, TG and LDL values as well as lower lipid ratio and atherogenic indices when compared to the positive control animals and the metoclopramide treated rats. The metoclopramide-treated rats showed the highest lipid values as well as the highest lipid ratio and atherogenic indices. Metoclopramide-induced hyperprolactinemia was associated with higher lipid values while bromocriptine-induced hypoprolactinaemia was associated with lower concentration of the lipid profile parameters. In summary, manipulation of endogenous PRL concentration can lead to hyperlipidaemia and thus contribute to an atherogenic phenotype.
For full copy of this document please visit the digital library help desk.
Tags: Albino Rats, Atherogenic Phenotype, Bromocriptine Trated Rats, Cholesterol, Hyperprolactinemia, Lipid Profile, Lipoproteins, Metoclopramide Treated Rats, Nnamdi Azikiwe University, Oparaji Chiedozie Kenneth